bioMérieux S.A. (ENXTPA:BIM) commences share repurchases on May 24, 2022, under the program mandated by the shareholders in the Annual General Meeting held on May 23, 2022. As per the mandate, the company is authorized to repurchase up to 10% of its share capital. The maximum purchase price of shares shall not be more than€250, excluding acquisition-related fees.

The purpose of repurchase program is to maintain a liquid market for the company's shares through market-making transactions carried out by an independent investment firm under a liquidity agreement that complies with the AMAFI code of ethics approved by the AMF, deliver shares upon the exercise of rights attached to the securities giving access to company's share capital, reduce the company's share capital by cancelling shares subject to the limits laid down by law, retain the shares purchased and swap them again at a later date for exchange or as payment as part of any external expansion acquisitions, implement any market practices permitted by the market authorities and to ensure the hedging of stock option plans and/or free share plans for the benefit of group employees and/or corporate officers. The authorization shall expire at the close of the Annual General Meeting called to approve the financial statements for the year ending December 31, 2022, or 18 months from this Annual General Meeting, whichever is the earlier.